TY - JOUR
T1 - Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy
AU - Maggen, Charlotte
AU - Dierickx, Daan
AU - Cardonick, Elyce
AU - Mhallem Gziri, Mina
AU - Cabrera-Garcia, Alvaro
AU - Shmakov, Roman G.
AU - Avivi, Irit
AU - Masturzo, Bianca
AU - Duvekot, Johannes J.
AU - Ottevanger, Petronella B.
AU - O’Laughlin, Andie
AU - Polushkina, Evgeniya
AU - van Calsteren, Kristel
AU - Woei-A-Jin, F. J. Sherida H.
AU - Amant, Frédéric
N1 - Funding Information: We thank all participating patients and all (para-)medical staff involved in registering cases in the INCIP database (see www.cancerinpregnancy.org). We especially thank INCIP investigators Carolina Balderas Delgado (CREHER clinic, Mexico) and Ingrid A. Boere (Erasmus MC, the Netherlands) for collecting cases and their scientific support. We thank the ESGO for their continued support. Funding Information: The European Union’s Horizon 2020 research and innovation programme under grant agreement No 647047 and Kom Op Tegen Kanker (Stand up to Cancer), the Flemish Cancer Society funds the INCIP. Frédéric Amant is the senior clinical investigator of the Research Foundation Flanders (F.W.O) and the project receives support from the ESGO. Publisher Copyright: © 2020 British Society for Haematology and John Wiley & Sons Ltd
PY - 2021/4
Y1 - 2021/4
N2 - This cohort study of the International Network on Cancer, Infertility and Pregnancy (INCIP) reports the maternal and neonatal outcomes of 80 pregnant patients diagnosed with non-Hodgkin lymphoma (NHL) between 1986 and 2019, focussing on 57 (71%) patients with diffuse large B-cell lymphoma (DLBCL). Of all 80 patients, 54 (68%) pregnant patients received chemotherapy; mostly (89%) CHOP-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens. Four early pregnancies were terminated. Among 76 ongoing pregnancies, there was one stillbirth (1·3%). Overall, there was a high incidence of small for gestational age neonates (39%), preterm delivery (52%), obstetric (41%) and neonatal complications (12·5%), and this could not exclusively be explained by the receipt of antenatal chemotherapy. Half of preterm deliveries (46%) were planned in order to tailor oncological treatment. The 3-year progression-free and overall survival for patients with DLBCL treated with rituximab-CHOP was 83·4% and 95·7% for limited stage (n = 29) and 60·6% and 73·3% for advanced stage (n = 15). Of 36 pregnant patients who received rituximab, five (13%) cases with neonatal complications and three (8%) with maternal infections were reported. In conclusion, standard treatment for DLBCL can be offered to pregnant patients in obstetric centres that cater for high-risk patients.
AB - This cohort study of the International Network on Cancer, Infertility and Pregnancy (INCIP) reports the maternal and neonatal outcomes of 80 pregnant patients diagnosed with non-Hodgkin lymphoma (NHL) between 1986 and 2019, focussing on 57 (71%) patients with diffuse large B-cell lymphoma (DLBCL). Of all 80 patients, 54 (68%) pregnant patients received chemotherapy; mostly (89%) CHOP-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens. Four early pregnancies were terminated. Among 76 ongoing pregnancies, there was one stillbirth (1·3%). Overall, there was a high incidence of small for gestational age neonates (39%), preterm delivery (52%), obstetric (41%) and neonatal complications (12·5%), and this could not exclusively be explained by the receipt of antenatal chemotherapy. Half of preterm deliveries (46%) were planned in order to tailor oncological treatment. The 3-year progression-free and overall survival for patients with DLBCL treated with rituximab-CHOP was 83·4% and 95·7% for limited stage (n = 29) and 60·6% and 73·3% for advanced stage (n = 15). Of 36 pregnant patients who received rituximab, five (13%) cases with neonatal complications and three (8%) with maternal infections were reported. In conclusion, standard treatment for DLBCL can be offered to pregnant patients in obstetric centres that cater for high-risk patients.
KW - R-CHOP
KW - diffuse large B-cell lymphoma
KW - maternal outcome
KW - non-Hodgkin lymphoma
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85091040825&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/bjh.17103
DO - https://doi.org/10.1111/bjh.17103
M3 - Article
C2 - 32945547
SN - 0007-1048
VL - 193
SP - 52
EP - 62
JO - British journal of haematology
JF - British journal of haematology
IS - 1
ER -